| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/HR.2011.101 |
| P698 | PubMed publication ID | 21796123 |
| P2093 | author name string | Kenjiro Kikuchi | |
| Naoki Nakagawa | |||
| Naoyuki Hasebe | |||
| Motoki Matsuki | |||
| Takayuki Fujino | |||
| Junko Chinda | |||
| Maki Kabara | |||
| NICE-Combi Study Group | |||
| P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects | Q28335101 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). | Q31437386 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group | Q34025761 | ||
| 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension | Q34201728 | ||
| Diuretic and natriuretic effects of nifedipine in healthy persons | Q34417466 | ||
| Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis. | Q37508558 | ||
| Revised equations for estimated GFR from serum creatinine in Japan | Q39513402 | ||
| Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity | Q39708158 | ||
| A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity | Q40126890 | ||
| A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker | Q42972309 | ||
| Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial | Q43156210 | ||
| Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT). | Q44026520 | ||
| Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 | ||
| Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial | Q45185743 | ||
| Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study | Q45232297 | ||
| Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. | Q46002051 | ||
| Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. | Q46419792 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). | Q46455386 | ||
| Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study | Q46691578 | ||
| Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease | Q46945045 | ||
| KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. | Q55043049 | ||
| The metabolic syndrome in hypertension: European society of hypertension position statement | Q56970717 | ||
| 2007 Guidelines for the Management of Arterial Hypertension | Q56970780 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 1121-1126 | |
| P577 | publication date | 2011-07-28 | |
| P1433 | published in | Hypertension Research | Q15762136 |
| P1476 | title | Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate | |
| P478 | volume | 34 |
| Q37255216 | Efficacies of Controlling Morning Blood Pressure and Protecting the Kidneys by Treatment With Valsartan and Nifedipine CR or Valsartan and Amlodipine (MONICA Study) |
| Q36720082 | Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease |
Search more.